---
schema_version: "secwatch.filing_event.v1"
accession: "0001459839-22-000035"
form_type: "8-K"
ticker: "SIBN"
cik: "0001459839"
company_name: "SI-BONE, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:43:27.522455+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SI-BONE Q2 revenue $25.6M (+15% YoY); net loss $18.5M ($0.54/share)

## Summary
- Record worldwide revenue $25.6M, up 15% YoY; U.S. revenue $23.8M, up 18% YoY.
- Gross margin 86% vs 89% YoY; operating loss $17.9M vs $13.0M.
- Net loss $18.5M ($0.54 per diluted share) vs $14.0M ($0.42) in Q2 2021.
- Cash $114.4M; long-term borrowings $35.1M; FY2022 revenue guidance reaffirmed at $106-108M.
- FDA clearances for iFuse-TORQ pelvic fractures and iFuse Bedrock Granite; CMS NTAP up to $9,828.

## SEC filing metadata
- accession: 0001459839-22-000035
- form_type: 8-K
- ticker: SIBN
- cik: 0001459839
- company_name: SI-BONE, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1459839/000145983922000035/0001459839-22-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1459839/000145983922000035/sibn-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001459839-22-000035
- JSON: https://secwatch.observer/filing/0001459839-22-000035.json
- Plain text: https://secwatch.observer/filing/0001459839-22-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.